Pharmaceutical development and optimization of azithromycin suppository for paediatric use

International Journal of Pharmaceutics

Volumn 441, Issue 1-2, 2013, Pages 218-226

  Kauss, Tina ^a   Gaubert, Alexandra ^a   Boyer, Chantal ^a   Ba, Boubakar B ^a   Manse, Muriel ^a   Massip, Stephane ^a   Léger, Jean Michel ^a   Fawaz, Fawaz ^a   Lembege, Martine ^a   Boiron, Jean Michel ^b   Lafarge, Xavier ^b   Lindegardh, Niklas ^c   White, Nicholas J ^c,d   Olliaro, Piero ^d,e   Millet, Pascal ^a   Gaudin, Karen ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Antibiotic; Azithromycin; Paediatric solid dispersion; Pharmaceutical development; Rectal; Suppository

Indexed keywords

AZITHROMYCIN; MACROGOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG STABILITY; FEASIBILITY STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MELTING POINT; NONHUMAN; PRIORITY JOURNAL; RABBIT; RURAL AREA; SOLID PHASE EXTRACTION; SUPPOSITORY; X RAY DIFFRACTION;

ADMINISTRATION, RECTAL; ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; CHILD, PRESCHOOL; DRUG COMPOUNDING; DRUG STABILITY; EXCIPIENTS; HUMANS; POLYETHYLENE GLYCOLS; RABBITS; SUPPOSITORIES; TROPICAL CLIMATE;

EID: 84872827650     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.11.040     Document Type: Article

References (45)

1. S.L. Andersen, A. Ager, P. McGreevy, B.G. Schuster, D. Wesche, R. Kuschner, C. Ohrt, W. Ellis, R. Rossan, and J. Berrman Activity of azithromycin as a blood schizonticide against rodent and human plasmodia in vivo Am. J. Trop. Med. Hyg. 52 1995 159 161
2. M.T. Ansari, S. Karim, N. Ranjha, m. Shah, and N.H.S. Muhammad Physicochemical characterization of artemether solid dispersions with hydrophilic carriers by freeze dried and melt methods Arch. Pharm. Res. 33 6 2010 901 910
3. E. Bergogne-Bérézin, and A. Bryskier The suppository form of antibiotic administration: pharmacokinetics and clinical application J. Antimicrob. Chemother. 43 1999 177 185
4. J.A. Berkley, B.S. Lowe, I. Mwangi, T. Williams, E. Bauni, S. Mwarumba, C. Ngetsa, M.P. Slack, S. Njenga, C.A. Hart, K. Maitland, M. English, K. Marsh, and J.A. Scott Bacteremia among children admitted to a rural hospital in Kenya N. Engl. J. Med. 352 2005 39 47
5. J.A. Berkley, K. Maitland, I. Mwangi, C. Ngetsa, S. Mwarumba, B.S. Lowe, C.R. Newton, K. Marsh, J.A. Scott, and M. English Use of clinical syndromes to target antibiotic prescribing in seriously ill children in malaria endemic area: observational study Br. Med. J. 330 7498 2005 995
6. E. Chevalier, M. Viana, A. Artaud, L. Chomette, S. Haddouchi, G. Devidts, and D. Chulia Comparison of three dissolution apparatuses for testing calcium phosphate pellets used as ibuprofen delivery systems AAPS PharmSciTech 10 2 2009 597 605
7. W.L. Chiou, and S. Riegelman Pharmaceutical applications of solid dispersion systems J. Pharm. Sci. 60 9 1971 1281 1302
8. D.Q.M. Craig The mechanisms of drug release from solid dispersions in water-soluble polymers Int. J. Pharm. 231 2002 131 144
9. F. Damian, N. Blaton, L. Naessens, J. Balzarini, R. Kinget, P. Augustijns, and G. Van Den Mooter Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14 Eur. J. Pharm. Sci. 10 2000 311 322
10. S. Djokic, G. Kobrehel, N. Lopotar, A. Nagl, and D. Mrvos Erythromycin series. XIII. Synthesis and structure elucidation of 10-dihydro-10-deoxo-11- methyl-11-azaerythromycine A J. Chem. Res. Synop. 5 1988 152 153
11. EMA European Medicines Agency Reflection Paper: Formulations of Choice for the Paediatric Population 2006 Available at: http://www.ema.europa.eu/docs/ en-GB/document-library/Scientific-guideline/2009/09/WC500003782.pdf (accessed in January 2012)
12. FDA Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms 1997 Center for Drug Evaluation and Research Rockville, MD Available at: http://www.fda.gov/cder/guidance.htm
13. R. Gandhi, O. Pillai, R. Thilagavathi, B. Gopalakrishnan, C.L. Kaul, and R. Panchagnula Characterization of azithromycin hydrates Eur. J. Pharm. Sci. 16 2002 175 184
14. K. Gaudin, T. Kauss, A. Gaubert, V. Viaud, J.P. Dubost, P.L. Olliaro, N. White, and P. Millet Simultaneous determination of artemether and azithromycin in suppository by reversed phase HPLC Anal. Lett. 44 2011 2732 2743
15. M.F. Gomes, M.A. Faiz, J.O. Gyapong, M. Warsame, T. Agbenyega, A. Babiker, F. Baiden, E.B. Yunus, F. Binka, C. Clerk, P. Folb, R. Hassan, M.A. Hossain, O. Kimbute, A. Kitua, S. Krishna, C. Makasi, N. Mensah, Z. Mrango, P. Olliaro, R. Peto, T.J. Peto, M.R. Rahman, I. Ribeiro, R. Samad, N.J. White, and Study 13 Research Group Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial Lancet 373 2009 557 566
16. M. Guyot, F. Fawaz, J. Bildet, F. Bonini, and A.M. Lagueny Physicochemical characterization and dissolution of norfloxacin: cyclodextrin inclusion compounds and PEG solid dispersions Int. J. Pharm. 123 1995 53 63
17. B. Iqbal, A. Ali, J. Ali, S. Baboota, S. Gupta, S. Dang, M. Shadab, and J.K. Sahni Recent advances and patents in solid dispersion technology Recent Pat. Drug Deliv. Formul. 5 3 2011 244 264
18. R.F. Jacobs, H.D. Maples, J.V. Aranda, G.M. Epinoza, C. Knirsch, R. Chandra, J.M. Fisher, and G.L. Kearns Pharmacokinetics of intravenously administered azithromycin in pediatric patients Pediatr. Infect. Dis. J. 24 2005 34 39
19. V. Jigar, V. Puja, and P. Jayvadan Formulation and evaluation of solid dispersions of rofecoxib for improvement of dissolution profile Afr. J. Pharm. Pharmacol. 5 2011 577 581
20. A. Kalia, and M. Poddar Solid dispersions: an approach towards enhancing dissolution rate Int. J. Pharm. Pharm. Sci. 3 4 2011 9 19
21. T. Kauss, K. Gaudin, A. Gaubert, B. Ba, S. Tagliaferri, F. Fawaz, J.L. Fabre, J.M. Boiron, X. Lafarge, N.J. White, P.L. Olliaro, and P. Millet Development of rectal forms of azithromycin as an alternative to oral and intra venous administration for paediatric treatment Int. J. Pharm. 436 2012 624 630
22. S. Khan, H. Batchelor, P. Hanson, Y. Perrie, and A.R. Mohammed Physicochemical characterization, drug polymer dissolution and in vitro evaluation of phenacetin and phenylbutazone solid dispersions with polyethylene glycol 8000 J. Pharm. Sci. 100 2011 4281 4294
23. H.D. Langtry, and J.A. Balfour Azithromycin: a review of its use in paediatric infectious diseases Drugs 56 1998 273 297
24. C. Leuner, and J. Dressman Improving drug solubility for oral delivery using solid dispersions Eur. J. Pharm. Biopharm. 50 2000 47 60
25. J.W. Moore, and H.H. Flanner Mathematical comparison of dissolution profiles Pharm. Technol. 1996 64 75
26. H. Noedl, S. Krudsood, W. Leowattana, N. Tangpukdee, W. Thanachartwet, S. Looareesuwan, R.S. Miller, M. Fukuda, K. Jongsakul, K. Yingyuen, S. Sriwichhai, C. Ohrt, and C. Knirsch In vitro antimalarial activity of azithromycin, artesunate and quinine in combination and correlation with clinical outcome Antimicrob. Agents Chemother. 51 2007 651 656
27. Noedl, H. Wernsdorfer, S. Krudsood, P. Wilairatana, H. Kollaritsch, G. Wiedermann, and S. Looareesuwan Antimalarial activity of azithromycin, artemisinin and dihydroartemisinin in fresh isolates of Plasmodium falciparum in Thailand Acta Trop. 80 2001 39 44
28. M. Palanisamy, and J. Khanam Solid dispersion of prednisolone: solid state characterization and improvement of dissolution profile Drug Dev. Ind. Pharm. 37 4 2011 373 386
29. K.R. Parmar, S.R. Shah, and N.R. Sheth Studies in dissolution enhancement of ezetimibe by solid dispersions in combination with a surface absorbent Dissolut. Tech. August 2011 55 61
30. ® (Azithromycin) US physician prescribing information, Pfizer official web page. Retrieved from: http://labeling.pfizer.com/ShowLabeling.aspx?id=511 at www.pfizer.com (accessed in January 2012).
31. J.C. Price Polyethylene glycol R.C. Rowe, P.J. Sheskey, P.J. Weller, Handbook of Pharmaceutical Excipients 2003 American Pharmaceutical Association/The Pharmaceutical Press Washington, DC/London
32. Sadoway, D., 2004. 3.091 Introduction to Solid State Chemistry: Phase Equilibria and Phase Diagrams, Fall 2004. Lecture Notes. MIT Open Coursware, pp. 1-28.
33. M. Saleem, M. Taher, S. Sanaullah, M. Najmuddin, A. Javed, S. Humaira, and S. Roshan Formulation and evaluation of tramadol hydrochloride rectal suppositories Indian J. Pharm. Sci. 70 2008 640 644
34. R.M. Shepard, and F.C. Falkner Pharmacokinetics of azithromycin in rats and dogs J. Antimicrob. Chemother. 25 Suppl. A 1990 49 60
35. D.O. Simba, M. Warsame, O. Kimbute, D. Kakoko, M. Petzold, G. Tomson, Z. Premji, and M. Gomes Factors influencing adherence to referral advice following pre-referral treatment with artesunate suppositories in children in rural Tanzania Trop. Med. Int. Health 14 2009 775 783
36. L.S. Stratchunsky, A.D. Nazarov, A.A. Firsov, and N.A. Petrachenkova Age dependence of erythromycin rectal bioavailability in children Eur. J. Drug Metab. Pharmacokinet. 3 1991 321 323
37. E.I. Taha, A.A.A. Zaghloul, A.A. Kassem, and M.A. Khan Salbutamol sulfate suppositories: influence of formulation on physical parameters and stability Pharm. Dev. Technol. 8 1 2003 21 30
38. F. Tajarobi, S. Abrahmsen-Alami, and A. Larsson Dissolution rate enhancement of parabens in PEG solid dispersions and its influence on the release from matrix tablets J. Pharm. Sci. 100 1 2011 275 283
39. M.A. Thera, F. Keita, M.S. Sissoko, O.B. Traoré, D. Coulibaly, M. Sacko, V. Lameyre, J.P. Ducret, and O. Doumbo Acceptability and efficacy of intra-rectal quinine alkaloids as a pre-transfer treatment of non-per os malaria in peripheral health care facilities in Mopti, Mali Malar. J. 6 2007 68
40. F. Van Bambeke, and P.M. Tulkens Macrolides: pharmacokinetics and pharmacodynamics Int. J. Antimicrob. Agents 18 2001 S17 S23
41. S.R. Vippagunta, Z. Wang, S. Hornung, and S.L. Krill Factors affecting the formulation of eutectic solid dispersions and their dissolution behavior J. Pharm. Sci. 96 2007 294 304
42. WHO Proposal to Waive In Vivo Bioequivalence Requirements for the WHO Model List of Essential Medicines Immediate Release, Solid Oral Dosage Forms 2005 World Health Organization Geneva, Switzerland Retrieved from http://www.who.int/medicines/services/expertcommittees/pharmprep/ QAS04-109Rev1-Waive-invivo-bioequiv.pdf (accessed in January 2012)
43. WHO Guidelines for the Treatment of Malaria 2nd ed. 2010 Retrieved from: http://www.whqlibdoc.who.int/publications/2010/9789241547925-eng.pdf (accessed in November 2012)
44. WHO World Health Organization Official Web Page 2012 Retrieved from: http://www.who.int (accessed in January 2012)
45. A.E. Yeo, and K.H. Rieckmann Increased antimalarial activity of azithromycin during prolonged exposure of Plasmodium falciparum in vitro Int. J. Parasitol. 25 1995 531 532